We use non-essential cookies (including anonymous analytics) to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential for our platform to work and help us to provide you with the best experience possible. You can accept or reject our non-essential cookies and change your mind at any time. To learn more, please read our cookies policy.

Update cookie preferences

Ovarian Cancer Action becomes NCRI partner

23 August 2022

Ovarian Cancer Action, Research Professor Ahmed Ahmed.jpg

Ovarian Cancer Action has joined the NCRI (National Cancer Research Institute) Partnership as a funder of cancer research

Ovarian Cancer Action joins 21 other funders of cancer research wishing to maximise the value and benefits of cancer research for patients and the public.

NCRI’s Partners include cancer research charities and funding bodies representing all four nations of the United Kingdom. They work together to coordinate their research, avoiding unnecessary duplication and maximising the impact of their research.

“Survival rates in ovarian cancer today are the same as breast cancer in the 1970s. Over the next decade our mission is to accelerate progress to transform survival rates for  women, and we can’t do this alone. Joining the NCRI Partnership means that we can collaborate with the top cancer research funders in the UK. As the UK’s largest specialist ovarian cancer research funder, we are excited to bring the voice of ovarian cancer patients to the NCRI Partnership to create the best future for women.” Cary Wakefield, CEO of Ovarian Cancer Action

Ovarian Cancer Action funds research into better diagnosis and treatments, raises awareness of risk and symptoms to improve prevention and early diagnosis, and gives a voice to all those affected by ovarian cancer. Since 2006, Ovarian Cancer Action has funded over £12 million in research projects and launched the first ever dedicated centre of ovarian cancer research in Europe. Their research is focussed on early detection and treatment of ovarian cancer in order to transform how long and how well women live after an ovarian cancer diagnosis.

Cary Wakefield added “In 2022, Ovarian Cancer Action will be publishing a new research strategy to spark a decisive decade in improving survival rates for women with ovarian cancer. We are starting as we mean to go on, supercharging our partnership with the leading ovarian cancer experts at our Ovarian Cancer Research Centre, and joining the NCRI Partnership to collaborate with the top cancer research funders in the UK. Together we will make ovarian cancer a survivable disease.” 

“We are really pleased to have Ovarian Cancer Action as part of the NCRI Partnership. They join at a great time as they prepare to publish a new research strategy and as the NCRI Groups are also identifying their research priorities. We hope that by working together with funders, researchers, patients and carers, we can advance research into ovarian cancer and improve outcomes for patients.” Dr Iain Frame, CEO, NCRI

As NCRI Partners, Ovarian Cancer Action will be able to share their expertise with other cancer research funders and learn from them. They will also connect with other funders that can lead to exciting and innovative research collaborations to improve patient outcomes.